Monika M. Kutyna

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

A Reliable Method for Thawing Primary AML and CMML Mononuclear Cells to Preserve Viability and Function.

A Reliable Method for Thawing Primary AML and CMML Mononuclear Cells to Preserve Viability and Function.

Journal: Bio-protocol
Published: March 17, 2026

Infection risk in myelodysplastic syndromes is dynamic and immune driven.

Infection risk in myelodysplastic syndromes is dynamic and immune driven.

Journal: Blood advances
Published: January 27, 2026

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm.

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm.

Journal: Blood advances
Published: March 05, 2025

RBC transfusion dependency refines the Molecular International Prognostic Scoring System for myelodysplastic syndrome.

RBC transfusion dependency refines the Molecular International Prognostic Scoring System for myelodysplastic syndrome.

Journal: Blood advances
Published: February 10, 2025

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.

Journal: Blood cancer journal
Published: December 27, 2024

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.

Journal: Blood advances
Published: November 04, 2024

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.

Journal: Blood cancer journal
Published: May 09, 2024

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

Journal: Leukemia
Published: April 28, 2024

Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.

Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.

Journal: Blood cancer discovery
Published: April 26, 2024

CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting.

CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting.

Journal: PloS one
Published: April 11, 2024

IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.

IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.

Journal: Blood
Published: December 18, 2023

A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data.

A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data.

Journal: Cancers
Published: May 27, 2023
Showing 1-12 of 22

Last Updated: 09/26/2026